MedAvail (MDVLQ) 10-Q 9 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Nov. 05, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-36533
Entity Registrant Name	MEDAVAIL HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0772394
Entity Address, Address Line One	6665 Millcreek Dr.
Entity Address, Address Line Two	Unit 1
Entity Address, City or Town	Mississauga
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L5N 5M4
City Area Code	905
Local Phone Number	812-0023
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MDVL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,848,154
Entity Central Index Key	0001402479
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 35,875	$ 57,936
Restricted cash	400	60
Accounts receivable (net of allowance for doubtful accounts of $27 thousand for September 30, 2021, $40 thousand for December 31, 2020)	1,075	1,520
Inventories	4,253	2,817
Prepaid expenses and other current assets	762	1,534
Total current assets	42,365	63,867
Property, plant and equipment, net	4,632	3,795
Right-of-use assets	2,902	1,239
Other assets	248	203
Intangible assets	1,950	227
Total assets	52,097	69,331
Current liabilities:
Accounts payable and accrued liabilities	7,075	4,512
Short-term debt	1,000	2,161
Contract liability	317	275
Current portion of lease obligations	742	665
Total current liabilities	9,134	7,613
Long-term debt, net	9,466	0
Long-term portion of lease obligations	2,279	651
Total liabilities	20,879	8,264
Commitments and contingencies
Stockholders' deficit:
Common shares ($0.001 par value, 100,000,000 shares authorized, 32,754,925 and 31,816,020 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively)	33	32
Warrants	1,373	2,614
Additional paid-in-capital	216,204	213,624
Accumulated other comprehensive loss	(6,928)	(6,928)
Accumulated deficit	(179,464)	(148,275)
Total stockholders' equity	31,218	61,067
Total liabilities and stockholders' equity	$ 52,097	$ 69,331

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 27	$ 40
Common shares, par value (in USD per share)	$ 0.001	$ 0.001
Common shares, authorized (in shares)	100,000,000	100,000,000
Common shares, issued (in shares)	32,754,925	31,816,020
Common shares, outstanding (in shares)	32,754,925	31,816,020

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Sales:
Total sales	$ 5,792	$ 7,145	$ 14,849	$ 10,868
Cost of sales:
Total cost of sales	5,606	2,162	14,170	5,459
Gross profit	186	4,983	679	5,409
Pharmacy operations	2,395	1,450	6,619	3,655
General and administrative	6,805	3,464	19,941	10,544
Selling and marketing	1,779	624	4,657	1,897
Research and development	232	154	601	532
Merger expenses	0	1,324	0	2,607
Operating loss	(11,025)	(2,033)	(31,139)	(13,826)
Other gain (loss), net	7	0	206	8
Interest income	7	0	74	15
Interest expense	(260)	(455)	(328)	(911)
Loss before income taxes	(11,271)	(2,488)	(31,187)	(14,714)
Income tax expense	(2)	0	(2)	0
Net loss	(11,273)	(2,488)	(31,189)	(14,714)
Other comprehensive income (loss):
Cumulative translation adjustment	0	0	0	(2)
Total comprehensive loss	$ (11,273)	$ (2,488)	$ (31,189)	$ (14,716)
Net loss per share - basic (in USD per share)	$ (0.34)	$ (1.22)	$ (0.96)	$ (7.60)
Net loss per share - diluted (in USD per share)	$ (0.34)	$ (1.22)	$ (0.96)	$ (7.60)
Weighted average shares outstanding - basic (in shares)	32,750,831	2,045,686	32,580,199	1,936,015
Weighted average shares outstanding - diluted (in shares)	32,750,831	2,045,686	32,580,199	1,936,015
Total pharmacy and hardware sales
Sales:
Total sales	$ 5,659	$ 3,926	$ 14,165	$ 7,587
Cost of sales:
Total cost of sales	5,539	2,132	13,744	5,343
Total service sales
Sales:
Total sales	133	3,219	684	3,281
Cost of sales:
Total cost of sales	$ 67	$ 30	$ 426	$ 116

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Shareholders' Equity (Deficit) - USD ($) $ in Thousands		Total	Common Shares	Warrants	Additional Paid-in-Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Temporary equity beginning balance (in shares) at Dec. 31, 2019	[1]	10,500,440
Temporary equity beginning balance at Dec. 31, 2019	[1]	$ 93,484
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of preferred shares (in shares)	[1]	102,777
Issuance of preferred shares	[1]	$ 788
Temporary equity ending balance (in shares) at Sep. 30, 2020	[1]	10,603,217
Temporary equity ending balance at Sep. 30, 2020	[1]	$ 94,272
Balance at beginning of period (in shares) at Dec. 31, 2019			1,504,251
Balance at beginning of period at Dec. 31, 2019			$ 8	$ 698	$ 30,829	$ (121,230)	$ (6,950)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(14,714)				(14,714)
Shares issued for options exercises (in shares)			32,276
Shares issued for options exercises		50			50
Share-based compensation		235			235
Warrants issued		611		622	(11)
Cumulative translation adjustment		(2)
Balance at end of period (in shares) at Sep. 30, 2020			1,536,527
Balance at end of period at Sep. 30, 2020			$ 8	1,320	31,103	(135,944)	(6,952)
Total equity and temporary equity at beginning of period at Dec. 31, 2019		(3,161)
Total equity and temporary equity at end of period at Sep. 30, 2020		$ (16,193)
Temporary equity beginning balance (in shares) at Jun. 30, 2020	[1]	10,603,217
Temporary equity beginning balance at Jun. 30, 2020	[1]	$ 94,272
Temporary equity ending balance (in shares) at Sep. 30, 2020	[1]	10,603,217
Temporary equity ending balance at Sep. 30, 2020	[1]	$ 94,272
Balance at beginning of period (in shares) at Jun. 30, 2020			1,523,995
Balance at beginning of period at Jun. 30, 2020			$ 8	1,315	31,019	(133,456)	(6,952)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(2,488)				(2,488)
Shares issued for options exercises (in shares)			12,532
Shares issued for options exercises		19			19
Share-based compensation		65			65
Warrants issued		5		5
Cumulative translation adjustment		0
Balance at end of period (in shares) at Sep. 30, 2020			1,536,527
Balance at end of period at Sep. 30, 2020			$ 8	1,320	31,103	(135,944)	(6,952)
Total equity and temporary equity at beginning of period at Jun. 30, 2020		(13,794)
Total equity and temporary equity at end of period at Sep. 30, 2020		$ (16,193)
Temporary equity beginning balance (in shares) at Dec. 31, 2020	[1]	0
Temporary equity beginning balance at Dec. 31, 2020	[1]	$ 0
Temporary equity ending balance (in shares) at Sep. 30, 2021	[1]	0
Temporary equity ending balance at Sep. 30, 2021	[1]	$ 0
Balance at beginning of period (in shares) at Dec. 31, 2020			31,816,020
Balance at beginning of period at Dec. 31, 2020		61,067	$ 32	2,614	213,624	(148,275)	(6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		$ (31,189)				(31,189)
Shares issued for options exercises (in shares)		144,101	144,101
Shares issued for options exercises		$ 241			241
Exercise of warrants (in shares)			794,804
Exercise of warrants		151	$ 1	(1,241)	1,391
Share-based compensation		948			948
Cumulative translation adjustment		0
Balance at end of period (in shares) at Sep. 30, 2021			32,754,925
Balance at end of period at Sep. 30, 2021		31,218	$ 33	1,373	216,204	(179,464)	(6,928)
Total equity and temporary equity at beginning of period at Dec. 31, 2020		61,067
Total equity and temporary equity at end of period at Sep. 30, 2021		$ 31,218
Temporary equity beginning balance (in shares) at Jun. 30, 2021	[1]	0
Temporary equity beginning balance at Jun. 30, 2021	[1]	$ 0
Temporary equity ending balance (in shares) at Sep. 30, 2021	[1]	0
Temporary equity ending balance at Sep. 30, 2021	[1]	$ 0
Balance at beginning of period (in shares) at Jun. 30, 2021			32,583,734
Balance at beginning of period at Jun. 30, 2021			$ 33	1,485	215,700	(168,191)	(6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(11,273)				(11,273)
Shares issued for options exercises (in shares)			0
Shares issued for options exercises		0			0
Exercise of warrants (in shares)			171,191
Exercise of warrants		27	$ 0	(112)	139
Share-based compensation		365			365
Cumulative translation adjustment		0
Balance at end of period (in shares) at Sep. 30, 2021			32,754,925
Balance at end of period at Sep. 30, 2021		31,218	$ 33	$ 1,373	$ 216,204	$ (179,464)	$ (6,928)
Total equity and temporary equity at beginning of period at Jun. 30, 2021		42,099
Total equity and temporary equity at end of period at Sep. 30, 2021		$ 31,218
[1]	$0.001 par value, 10,000,000 shares authorized at September 30, 2021 and December 31, 2020. $0.001 par value, 16,638,421 shares authorized at September 30, 2020.

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Shareholders' Equity (Deficit) (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]
Redeemable preferred shares, par value (in USD per share)	$ 0.001	$ 0.001	$ 0.001
Redeemable preferred shares, authorized (in shares)	10,000,000	10,000,000	16,638,421

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (31,189)	$ (14,714)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment	928	721
Amortization of intangible and leased assets, and debt discount	877	525
Bad debt and other non cash receivables adjustments	47	39
Interest accretion on debt and finance leases	0	834
Unrealized foreign currency gain	0	(2)
Other loss	0	67
Share-based compensation expense	948	235
Warrant expense	0	174
PPP loan forgiveness gain	(161)	0
Changes in operating assets and liabilities:
Change in accounts receivable	398	(243)
Change in inventory	(2,511)	(243)
Change in prepaid expenses and other current assets	772	(117)
Change in accounts payable, accrued expenses and other liabilities	2,180	2,427
Change in contract liability	42	(4,694)
Change in operating lease liability due to cash payments	(505)	(336)
Net cash used in operating activities	(28,174)	(15,327)
Cash flows from investing activities:
Purchase of property, plant and equipment	(680)	(419)
Payment of security deposits	(45)	(114)
Purchase of intangible assets and other assets	(1,544)	(82)
Net cash used in investing activities	(2,269)	(615)
Cash flows from financing activities:
Issuance of common shares upon exercise of options and warrants	392	39
Issuance of preferred shares	0	788
Proceeds from debt	10,000	8,498
Payment of debt issuance costs	(624)	(69)
Repayment of debt	(1,000)	0
Payments on finance lease obligations	(46)	(16)
Net cash provided by financing activities	8,722	9,240
Net decrease in cash, cash equivalents and restricted cash	(21,721)	(6,702)
Cash, cash equivalents and restricted cash at beginning of period	57,996	8,849
Cash, cash equivalents and restricted cash at end of period	36,275	2,147
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment	1,075	1,182
Property, plant and equipment transferred to intangible assets	46	0
Purchase of property, plant and equipment in accounts payable	56	62
Purchase of intangible assets in accounts payable	398	36
Conversion of other liability amount into warrants	0	448
Lease liabilities arising from obtaining right of use assets:
Operating leases	2,177	590
Finance leases	$ 97	$ 164

NATURE OF OPERATIONS

NATURE OF OPERATIONS	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONS MedAvail Holdings, Inc., a Delaware corporation, or , MedAvail, or the Company, is a telehealth-enabled pharmacy technology company that has developed and commercialized an innovative self-service pharmacy, mobile application, kiosk and drive-thru solution. MedAvail's principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter facilitates live pharmacist counselling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control. MedAvail also operates SpotRx, or the Pharmacy, which is a full-service retail pharmacy utilizing the Company’s MedCenter technology. MedAvail also sells the MedCenter technology, which includes the MedCenter hardware, software, and related support services to customers such as healthcare providers and retailers for use within their own pharmacy operations. Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to our ability to continue as a going concern. If substantial doubt does exist, then management should determine if there are plans in place which alleviate that doubt. For the current nine months ended September 30, 2021, the Company has a net loss of $31.2 million, and negative cash flows from operations of $28.2 million. The Company's accumulated deficit as of September 30, 2021 is $179.5 million. Management has determined that there is not substantial doubt as to the Company’s ability to continue as a going concern. Our current cash on hand combined with our current borrowing capacity is expected to provide liquidity for the Company to support operations and growth for at least the next 12 months from the date of issuance of these unaudited interim consolidated condensed financial statements. However, we may have to raise additional capital to continue to fund our operations. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our growth strategy and capital market conditions. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited consolidated condensed financial statements as of September 30, 2021 and for the three and nine months ended September 30, 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information. Accordingly, the unaudited interim consolidated condensed financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The consolidated condensed balance sheet as of December 31, 2020 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2020 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 31, 2021, or the 2020 Form 10-K. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated condensed financial statements in the period they are deemed to be necessary. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact our clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated condensed financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. Principles of consolidation The unaudited consolidated condensed financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include, MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. This ASU will be effective beginning in the first quarter of our fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated condensed financial statements and related disclosures. Recently Adopted Accounting Standards Simplifying the Accounting for Income Taxes In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”). This guidance removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. This guidance also clarifies and simplifies other areas of ASC 740. This ASU was effective beginning in the first quarter of our fiscal year 2021. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. MedAvail assessed the impact of the new accounting standard on its consolidated condensed financial statements to facilitate its required adoption of the new standard on January 1, 2021. The adoption of ASU 2019-12 did not result in a material change to our consolidated condensed financial statements. Debt with Conversion and Other Options In August 2020, the FASB issued ASU No. 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting For Convertible Instruments and Contracts in an Entity's Own Equity” (“ASU 2020-06”). The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU also simplifies the diluted net income per share calculation in certain areas. MedAvail assessed the impact of the new accounting standard on its consolidated condensed financial statements to facilitate its early adoption of the new standard on January 1, 2021. The adoption of ASU 2020-06 did not result in a material change to our consolidated condensed financial statements. There were no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated condensed financial statements through the reporting date.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHAREBasic earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period. The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period they were outstanding up to when they were exercised. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 58,518 November 18, 2020 May 10, 2021 During the three and nine months ended September 30, 2021 and 2020, there was no dilutive effect from stock options or other warrants due to the Company’s net loss position. Weighted average shares for historical periods have been adjusted for the effect of the 1.26 for 1 split on November 17, 2020. The following table sets forth the computation of basic and diluted earnings per share. Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except share and per share amounts) 2021 2020 2021 2020 Net loss - basic and diluted $ (11,273) $ (2,488) $ (31,189) $ (14,714) Weighted average shares - basic and diluted 32,750,831 2,045,686 32,580,199 1,936,015 Net loss per share - basic and diluted $ (0.34) $ (1.22) $ (0.96) $ (7.60) As of September 30, 2021 and 2020, there were 2.9 million and 2.2 million, respectively, of option awards outstanding that were not included in the diluted shares calculation because their inclusion would have been antidilutive.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (In thousands) September 30, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 35,875 $ 35,875 $ — $ — Restricted cash 400 400 — — Total assets $ 36,275 $ 36,275 $ — $ — Fair Value Hierarchy (In thousands) December 31, 2020 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 57,936 $ 57,936 $ — $ — Restricted cash 60 60 — — Total assets $ 57,996 $ 57,996 $ — $ — The carrying amount of the Company’s short-term notes and PPP loan approximates fair value due to their short-term nature and the loans carry a current market rate, a Level 2 input. The carrying amount of the Company's term loan approximates fair value based upon market interest rates available to us for debt of similar risk and maturities, a Level 2 input. Refer to Note 7, Debt, for further information.

BALANCE SHEET AND OTHER INFORMA

BALANCE SHEET AND OTHER INFORMATION	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET AND OTHER INFORMATION	BALANCE SHEET AND OTHER INFORMATION Restricted cash MedAvail considers cash to be restricted when withdrawal or general use is legally restricted. During the three months ended September 30, 2021, MedAvail recovered the prior $0.06 million restricted cash balance that was held as a guarantee for certain purchasing cards. During the same period, pursuant to a Loan and Security Agreement with Silicone Valley Bank (See Note 7), MedAvail issued letters of credit to secure certain operating leases, and MedAvail is required to maintain a $0.40 million balance with the bank to secure the outstanding letters of credit. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in the balance for cash presented in the statements of cash flows. Inventories The following table presents detail of inventory balances: September 30, December 31, (In thousands) 2021 2020 Inventories: MedCenter hardware $ 1,739 $ 1,655 Pharmacy 1,985 837 Spare parts 529 325 Total inventories $ 4,253 $ 2,817 Pharmacy inventory was recognized in pharmacy and hardware cost of sales at $5.0 million an $1.9 million during the three months ended September 30, 2021 and 2020, respectively, and $12.2 million and $4.8 million during the nine months ended September 30, 2021 and 2020, respectively. MedCenter hardware was recognized in pharmacy and hardware cost of sales at $0.13 million and $0.04 million during the three months ended September 30, 2021 and 2020, respectively, and $0.48 million and $0.14 million during the nine months ended September 30, 2021 and 2020, respectively. Property, plant and equipment The following tables present property, plant and equipment balances: Estimated useful lives September 30, December 31, (In thousands) 2021 2020 Property, plant and equipment: MedCenter equipment 5 years $ 5,268 $ 4,622 IT equipment 1 - 3 years 2,269 1,999 Leasehold improvements lesser of useful life or term of lease 866 799 General plant and equipment 5 - 8 years 567 353 Office furniture and equipment 5 - 8 years 369 329 Vehicles 5 years 54 54 Construction-in-process 534 90 Total historical cost 9,927 8,246 Accumulated depreciation (5,295) (4,451) Total property, plant and equipment, net $ 4,632 $ 3,795 Depreciation expense of property and equipment was $0.3 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively, and $0.9 million and $0.7 million for the nine months ended September 30, 2021 and 2020, respectively. Depreciation expense included in pharmacy and hardware cost of sales was $0.04 million and $0.05 million for the three months ended September 30, 2021 and 2020, respectively, and $0.13 million and $0.15 million for the nine months ended September 30, 2021 and 2020, respectively. Intangible assets The following table presents intangible asset balances: September 30, December 31, (In thousands) 2021 2020 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 3,731 1,815 Website and mobile application 583 583 Total intangible assets 8,171 6,255 Accumulated amortization: Intellectual property (3,857) (3,857) Software (1,781) (1,588) Website and mobile application (583) (583) Total accumulated amortization (6,221) (6,028) Total intangible assets, net $ 1,950 $ 227 Amortization expense of intangible assets was $0.09 million and $0.01 million for the three months ended September 30, 2021 and 2020, respectively, and $0.19 million and $0.07 million for the nine months ended September 30, 2021 and 2020, respectively, and are included in operating expenses. Software includes internal use software costs that are accounted for in accordance with ASC 350. Costs associated with application development are capitalized as intangible assets. All other costs including planning, training, and conceptual evaluation are expensed. Lessee leases Balance sheet amounts for lease assets and leases liabilities are as follows: September 30, December 31, (In thousands) 2021 2020 Assets: Operating $ 2,720 $ 1,108 Finance 182 131 Total assets $ 2,902 $ 1,239 Liabilities: Operating: Current $ 661 $ 612 Long-term 2,178 572 Finance: Current 81 53 Long-term 101 79 Total liabilities $ 3,021 $ 1,316 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: September 30, December 31, (In thousands) 2021 2020 Finance leases: Weighted-average remaining lease term (years) 1.8 2.4 Weighted-average discount rate 8.7 % 6.0 % Operating leases: Weighted-average remaining lease term (years) 4.1 2.5 Weighted-average discount rate 6.8 % 6.0 % Maturities of operating leases liabilities are as follows, in thousands: Remaining period in 2021 $ 176 2022 884 2023 773 2024 562 2025 478 2026 410 Thereafter 26 Total lease payments 3,309 Less: present value discount (470) Total leases $ 2,839 Maturities of finance lease liabilities are as follows, in thousands: Remaining period in 2021 $ 24 2022 95 2023 65 2024 19 2025 — 2026 — Thereafter — Total finance lease payments 203 Less: imputed interest (21) Total leases $ 182 Operating lease expense was $0.3 million and $0.2 million for the three months ended September 30, 2021 and 2020, respectively, and $0.7 million and $0.5 million for the nine months ended September 30, 2021 and 2020, respectively.

DEBT

DEBT	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
DEBT	DEBT The following table presents debt balances at September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) 2021 2020 Short-term note due May 2021 $ — $ 1,000 Short-term note due November 2021 1,000 1,000 PPP loan — 161 Term loan 10,039 — Term loan issuance costs, net (573) — Total debt, net 10,466 2,161 Less short term debt (1,000) (2,161) Long-term debt, net $ 9,466 $ — Short-term notes The notes do not accrue interest and may be repaid early without penalty. On May 14, 2021 the Company repaid $1.0 million on the Short-term note in accordance with the maturity schedule. PPP loan MedAvail received forgiveness approval of the loan on March 30, 2021 in accordance with the terms of the CARES Act. Term loan On June 7, 2021, the Company entered into a Loan and Security Agreement, or the Loan Agreement, with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., pursuant to which we borrowed $10.0 million in aggregate initial term loans, or the Initial Loans. The Company may borrow up to an additional $20.0 million in aggregate term loans (or, together with the Initial Loans, the Loans) on or before April 30, 2022, subject to no material adverse change or event of default (each as defined in the Loan Agreement) having occurred and continuing. The Loans and the Company's obligations under the Loan Agreement are guaranteed by certain of our subsidiaries and are secured by substantially all of the assets of the Company and its subsidiary guarantors. The Loans mature on April 1, 2026. Principal repayment will commence on May 1, 2024 in equal monthly installments of the outstanding Loan balance through the maturity date. The Loans bear interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% (7.25% at September 30, 2021). The Company may elect to prepay the Loans, in whole but not in part, at any time. If the Company elects to voluntarily prepay the Loans before the scheduled maturity date, the Company is required to pay the lenders a prepayment premium, equal to 3.0% of the outstanding principal balance if the prepayment occurs on or before June 7, 2022, 2.0% of the outstanding principal balance if the prepayment occurs on or before June 7, 2023, or 1.0% for a prepayment made after June 7, 2023, but before the scheduled maturity date. A prepayment premium is also applicable to a mandatory prepayment of the Loans upon an acceleration of the Loans. Upon a voluntary or mandatory prepayment of the Loans, the Company is also required to pay the lenders’ expenses and all accrued but unpaid interest on the Loans through the prepayment date. A final payment fee equal to 4.75% of the original principal amount of the Loans advanced will be due at the earlier of the maturity date, acceleration of the Loans, or a voluntary or mandatory prepayment of the Loans. The final payment fee is accreted to the Loan balance over the loan term using the effective interest method. The Loan Agreement includes customary representations and covenants that, subject to exceptions and qualifications, restrict the Company's ability to do the following things: engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; engage in businesses that are not related to existing business; add or change business locations; incur additional indebtedness; incur additional liens; make loans and investments; declare dividends or redeem or repurchase equity interests; and make certain amendments or payments in respect of any subordinated debt. In addition, the Loan Agreement contains customary affirmative covenants, including covenants regarding the payment of taxes and other obligations, maintenance of insurance, maintenance of our bank accounts, protection of our intellectual property, reporting requirements, compliance with applicable laws and regulations, and formation or acquisition of new subsidiaries. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued and unpaid interest under the Loan Agreement immediately due and payable and may exercise the other rights and remedies provided for under the Loan Agreement and related loan documents. The events of default under the Loan Agreement include, subject to grace periods in certain instances, payment defaults, breaches of covenants or representations and warranties, a material adverse change as defined in the Loan Agreement and with respect to certain governmental approvals, material judgments and attachments, cross defaults with certain other material indebtedness, bankruptcy and insolvency events with respect to the Company and its subsidiaries, and delisting of the Company's shares from NASDAQ. Loan issuance costs of $0.6 million are included in long term debt and are amortized to interest expense over the loan term using the effective interest method.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company incurred minimal income tax expense for the three and nine months ended September 30, 2021, respectively, due to ongoing losses and minimum state income tax obligations. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses. As of September 30, 2021, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Following MYOS Rens Technology Inc.’s, or MYOS’s and MedAvail, Inc.’s, or MAI's, announcement of the execution of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Court of the State of New York, County of New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020), or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation. The Demands and the Complaints that comprise the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MedAvail aided and abetted such breach of fiduciary duties. MYOS and MAI believe that the claims asserted in the Litigation are without merit, and believe that the Form S-4 Registration Statement disclosed all material information concerning the Merger and no supplemental disclosure is required under applicable law. However, in order to avoid the risk of the Litigation delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, MYOS determined to voluntarily supplement the Form S-4 Registration Statement as described in the Current Report on Form 8-K on November 2, 2020. Subsequently, the Nevada Complaint and the New York Complaint were voluntarily dismissed. The remainder of the Litigation remains outstanding. MYOS and MAI specifically deny all allegations in the Litigation and/or that any additional disclosure was or is required.

SHARE-BASED COMPENSATION EXPENS

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
SHARE-BASED COMPENSATION EXPENSE AND WARRANTS	SHARE-BASED COMPENSATION AND WARRANTS Share-based compensation The following table presents the Company's expense related to share-based compensation, in thousands: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Share-based compensation $ 365 $ 65 $ 948 $ 235 The share-based compensation expense for the three and nine months ended September 30, 2021, included $0.03 million from 2020 ESPP expense. Expense remaining to be recognized for unvested awards from the 2012, 2018, and 2020 plans as of September 30, 2021 was $3.8 million, which will be recognized on a weighted average basis over the next 3.0 years. The following table presents the Company's outstanding option awards activity during the nine months ended September 30, 2021: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,439,020 $ 1.59 $ 0.77 $ 32,791 Granted 670,850 8.14 4.44 — Exercised/Released (144,101) 1.67 $ 14.66 0.83 1,872 Cancelled/Forfeited (1,909) 1.65 0.83 24 Outstanding, end of period 2,963,860 $ 3.05 $ 1.59 7.99 $ 3,173 Vested and exercisable, end of the period 1,854,062 1.88 0.91 7.34 2,438 Vested and unvested exercisable, end of the period 1,854,062 1.88 0.91 7.34 2,348 Vested and expected to vest, end of the period 2,865,212 2.98 1.55 7.95 3,122 During the nine months ended September 30, 2021, the Company granted approximately 285,899 restricted stock units or RSUs to employees with a weighted average fair value of $6.50 per RSU and total aggregate intrinsic value of $1.9 million. None of the RSUs were vested as of September 30, 2021, and expense remaining to be recognized for unvested awards of $1.4 million will be recognized on a weighted average basis over the next 2.7 years. As of September 30, 2021 and December 31, 2020, there was an aggregate of 4.2 million and 5.0 million shares of common stock, respectively, available for grant under the 2020 Plan. Warrants During the nine months ended September 30, 2021 no warrants were issued. During the nine months ended September 30, 2021, warrants were exercised in exchange for issuing 794,804 shares of the Company’s common stock with total cash proceeds of $151 thousand. Warrants exercised during the nine months ended September 30, 2021, included 565,496 held by related parties (investors), with 626,339 related party warrants outstanding as of September 30, 2021.

REVENUE AND SEGMENT REPORTING

REVENUE AND SEGMENT REPORTING	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
REVENUE AND SEGMENT REPORTING	REVENUE AND SEGMENT REPORTINGOperating segments are the individual operations that the chief operating decision maker ("CODM"), who is our chief executive officer, reviews for purposes of assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The retail pharmacy services and pharmacy technology operating segments both engage in different business activities from which they earn revenues and incur expenses. The Company has the following two reportable segments: Retail Pharmacy Services Segment Retail pharmacy services segment revenue consists of products sold directly to consumers at the point of sale. MedAvail recognizes retail pharmacy sales revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts. Pharmacy Technology Segment The pharmacy technology segment consists of sales and subscriptions of MedPlatform systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. This generally includes either an initial lump sum payment upon installation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services for subscription agreements. In September 2020, the Company and a significant customer agreed that MedAvail had no further obligation to the customer and therefore would have no additional deliverables related to the contract liability balance, of which $4.7 million was outstanding as of December 31, 2019. As such, the Company recognized $4.7 million of revenue related to this contract during 2020. The contract revenue recognized consisted of $1.5 million of hardware sales revenue and $3.2 million of software integration for contract obligations for software programming and hardware development that were in progress but not completed. The following table presents sales and costs of sales by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Total Three Months Ended September 30, 2021 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 5,445 $ — $ 5,445 Hardware — 106 106 Subscription sales — 108 108 Total pharmacy and hardware sales 5,445 214 5,659 Service sales: Software integration — — — Software — 51 51 Maintenance and support — 44 44 Installation — 11 11 Professional services and other — 27 27 Total service sales — 133 133 Total sales 5,445 347 5,792 Cost of sales 5,366 240 5,606 Gross profit $ 79 $ 107 $ 186 Retail Pharmacy Services Pharmacy Technology (1) Total Three Months Ended September 30, 2020 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 2,186 $ — $ 2,186 Hardware — 1,625 1,625 Subscription sales — 115 115 Total pharmacy and hardware sales 2,186 1,740 3,926 Service sales: Software integration — 3,168 3,168 Software — 15 15 Maintenance and support — 17 17 Installation — — — Professional services and other — 19 19 Total service sales — 3,219 3,219 Total sales 2,186 4,959 7,145 Cost of sales 2,042 120 2,162 Gross profit $ 144 $ 4,839 $ 4,983 (1) Includes $1.5 million of hardware sales and $3.2 million of software integration sales associated with a non-recurring commercial agreement . Retail Pharmacy Services Pharmacy Technology Total Nine Months Ended September 30, 2021 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 13,357 $ — $ 13,357 Hardware — 470 470 Subscription sales — 338 338 Total pharmacy and hardware sales 13,357 808 14,165 Service sales: Software integration — — — Software — 125 125 Maintenance and support — 115 115 Installation — 39 39 Professional services and other — 405 405 Total service sales — 684 684 Total sales 13,357 1,492 14,849 Cost of sales 13,130 1,040 14,170 Gross profit $ 227 $ 452 $ 679 Retail Pharmacy Services Pharmacy Technology (1) Total Nine Months Ended September 30, 2020 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 5,196 $ — $ 5,196 Hardware — 2,048 2,048 Subscription sales — 343 343 Total pharmacy and hardware sales 5,196 2,391 7,587 Service sales: Software integration — 3,168 3,168 Software — 25 25 Maintenance and support — 40 40 Installation — 28 28 Professional services and other — 20 20 Total service sales — 3,281 3,281 Total sales 5,196 5,672 10,868 Cost of sales 5,059 400 5,459 Gross profit $ 137 $ 5,272 $ 5,409 (1) Includes $1.5 million of hardware sales and $3.2 million of software integration sales associated with a non-recurring commercial agreement. The following table presents assets and liabilities by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Corporate Total September 30, 2021 Assets $ 11,867 $ 4,740 $ 35,490 $ 52,097 Liabilities $ 5,976 $ 4,108 $ 10,795 $ 20,879 December 31, 2020 Assets $ 6,012 $ 5,547 $ 57,772 $ 69,331 Liabilities $ 2,203 $ 3,422 $ 2,639 $ 8,264 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets, in thousands: September 30, December 31, 2021 2020 Long-lived assets: United States $ 7,108 $ 4,533 Canada 426 501 Total long-lived assets $ 7,534 $ 5,034

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated condensed financial statements as of September 30, 2021 and for the three and nine months ended September 30, 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information. Accordingly, the unaudited interim consolidated condensed financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The consolidated condensed balance sheet as of December 31, 2020 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2020 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 31, 2021, or the 2020 Form 10-K. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated condensed financial statements in the period they are deemed to be necessary. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact our clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in
Principles of consolidation	Principles of consolidation The unaudited consolidated condensed financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include, MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.
Recently Adopted Accounting Standards	Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. This ASU will be effective beginning in the first quarter of our fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated condensed financial statements and related disclosures. Recently Adopted Accounting Standards Simplifying the Accounting for Income Taxes In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”). This guidance removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. This guidance also clarifies and simplifies other areas of ASC 740. This ASU was effective beginning in the first quarter of our fiscal year 2021. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. MedAvail assessed the impact of the new accounting standard on its consolidated condensed financial statements to facilitate its required adoption of the new standard on January 1, 2021. The adoption of ASU 2019-12 did not result in a material change to our consolidated condensed financial statements. Debt with Conversion and Other Options In August 2020, the FASB issued ASU No. 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting For Convertible Instruments and Contracts in an Entity's Own Equity” (“ASU 2020-06”). The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU also simplifies the diluted net income per share calculation in certain areas. MedAvail assessed the impact of the new accounting standard on its consolidated condensed financial statements to facilitate its early adoption of the new standard on January 1, 2021. The adoption of ASU 2020-06 did not result in a material change to our consolidated condensed financial statements. There were no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated condensed financial statements through the reporting date.

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Warrants Included in Earnings per Share	The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period they were outstanding up to when they were exercised. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 58,518 November 18, 2020 May 10, 2021
Schedule of Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share. Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except share and per share amounts) 2021 2020 2021 2020 Net loss - basic and diluted $ (11,273) $ (2,488) $ (31,189) $ (14,714) Weighted average shares - basic and diluted 32,750,831 2,045,686 32,580,199 1,936,015 Net loss per share - basic and diluted $ (0.34) $ (1.22) $ (0.96) $ (7.60)

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (In thousands) September 30, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 35,875 $ 35,875 $ — $ — Restricted cash 400 400 — — Total assets $ 36,275 $ 36,275 $ — $ — Fair Value Hierarchy (In thousands) December 31, 2020 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 57,936 $ 57,936 $ — $ — Restricted cash 60 60 — — Total assets $ 57,996 $ 57,996 $ — $ —

BALANCE SHEET AND OTHER INFOR_2

BALANCE SHEET AND OTHER INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	The following table presents detail of inventory balances: September 30, December 31, (In thousands) 2021 2020 Inventories: MedCenter hardware $ 1,739 $ 1,655 Pharmacy 1,985 837 Spare parts 529 325 Total inventories $ 4,253 $ 2,817
Schedule of Property, Plant and Equipment and Useful Lives	The following tables present property, plant and equipment balances: Estimated useful lives September 30, December 31, (In thousands) 2021 2020 Property, plant and equipment: MedCenter equipment 5 years $ 5,268 $ 4,622 IT equipment 1 - 3 years 2,269 1,999 Leasehold improvements lesser of useful life or term of lease 866 799 General plant and equipment 5 - 8 years 567 353 Office furniture and equipment 5 - 8 years 369 329 Vehicles 5 years 54 54 Construction-in-process 534 90 Total historical cost 9,927 8,246 Accumulated depreciation (5,295) (4,451) Total property, plant and equipment, net $ 4,632 $ 3,795
Schedule of Finite-Lived Intangible Assets	The following table presents intangible asset balances: September 30, December 31, (In thousands) 2021 2020 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 3,731 1,815 Website and mobile application 583 583 Total intangible assets 8,171 6,255 Accumulated amortization: Intellectual property (3,857) (3,857) Software (1,781) (1,588) Website and mobile application (583) (583) Total accumulated amortization (6,221) (6,028) Total intangible assets, net $ 1,950 $ 227
Schedule of Lease Assets and Liabilities	Balance sheet amounts for lease assets and leases liabilities are as follows: September 30, December 31, (In thousands) 2021 2020 Assets: Operating $ 2,720 $ 1,108 Finance 182 131 Total assets $ 2,902 $ 1,239 Liabilities: Operating: Current $ 661 $ 612 Long-term 2,178 572 Finance: Current 81 53 Long-term 101 79 Total liabilities $ 3,021 $ 1,316 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: September 30, December 31, (In thousands) 2021 2020 Finance leases: Weighted-average remaining lease term (years) 1.8 2.4 Weighted-average discount rate 8.7 % 6.0 % Operating leases: Weighted-average remaining lease term (years) 4.1 2.5 Weighted-average discount rate 6.8 % 6.0 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating leases liabilities are as follows, in thousands: Remaining period in 2021 $ 176 2022 884 2023 773 2024 562 2025 478 2026 410 Thereafter 26 Total lease payments 3,309 Less: present value discount (470) Total leases $ 2,839
Schedule of Maturities of Finance Lease Liabilities	Maturities of finance lease liabilities are as follows, in thousands: Remaining period in 2021 $ 24 2022 95 2023 65 2024 19 2025 — 2026 — Thereafter — Total finance lease payments 203 Less: imputed interest (21) Total leases $ 182

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Debt	The following table presents debt balances at September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) 2021 2020 Short-term note due May 2021 $ — $ 1,000 Short-term note due November 2021 1,000 1,000 PPP loan — 161 Term loan 10,039 — Term loan issuance costs, net (573) — Total debt, net 10,466 2,161 Less short term debt (1,000) (2,161) Long-term debt, net $ 9,466 $ —

SHARE-BASED COMPENSATION EXPE_2

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of MedAvail Share-based Compensation Expense	The following table presents the Company's expense related to share-based compensation, in thousands: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Share-based compensation $ 365 $ 65 $ 948 $ 235
Share-based Payment Arrangement, Option, Activity	The following table presents the Company's outstanding option awards activity during the nine months ended September 30, 2021: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,439,020 $ 1.59 $ 0.77 $ 32,791 Granted 670,850 8.14 4.44 — Exercised/Released (144,101) 1.67 $ 14.66 0.83 1,872 Cancelled/Forfeited (1,909) 1.65 0.83 24 Outstanding, end of period 2,963,860 $ 3.05 $ 1.59 7.99 $ 3,173 Vested and exercisable, end of the period 1,854,062 1.88 0.91 7.34 2,438 Vested and unvested exercisable, end of the period 1,854,062 1.88 0.91 7.34 2,348 Vested and expected to vest, end of the period 2,865,212 2.98 1.55 7.95 3,122

REVENUE AND SEGMENT REPORTING (

REVENUE AND SEGMENT REPORTING (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of Revenue and Costs of Sales by Segment	The following table presents sales and costs of sales by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Total Three Months Ended September 30, 2021 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 5,445 $ — $ 5,445 Hardware — 106 106 Subscription sales — 108 108 Total pharmacy and hardware sales 5,445 214 5,659 Service sales: Software integration — — — Software — 51 51 Maintenance and support — 44 44 Installation — 11 11 Professional services and other — 27 27 Total service sales — 133 133 Total sales 5,445 347 5,792 Cost of sales 5,366 240 5,606 Gross profit $ 79 $ 107 $ 186 Retail Pharmacy Services Pharmacy Technology (1) Total Three Months Ended September 30, 2020 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 2,186 $ — $ 2,186 Hardware — 1,625 1,625 Subscription sales — 115 115 Total pharmacy and hardware sales 2,186 1,740 3,926 Service sales: Software integration — 3,168 3,168 Software — 15 15 Maintenance and support — 17 17 Installation — — — Professional services and other — 19 19 Total service sales — 3,219 3,219 Total sales 2,186 4,959 7,145 Cost of sales 2,042 120 2,162 Gross profit $ 144 $ 4,839 $ 4,983 (1) Includes $1.5 million of hardware sales and $3.2 million of software integration sales associated with a non-recurring commercial agreement . Retail Pharmacy Services Pharmacy Technology Total Nine Months Ended September 30, 2021 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 13,357 $ — $ 13,357 Hardware — 470 470 Subscription sales — 338 338 Total pharmacy and hardware sales 13,357 808 14,165 Service sales: Software integration — — — Software — 125 125 Maintenance and support — 115 115 Installation — 39 39 Professional services and other — 405 405 Total service sales — 684 684 Total sales 13,357 1,492 14,849 Cost of sales 13,130 1,040 14,170 Gross profit $ 227 $ 452 $ 679 Retail Pharmacy Services Pharmacy Technology (1) Total Nine Months Ended September 30, 2020 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 5,196 $ — $ 5,196 Hardware — 2,048 2,048 Subscription sales — 343 343 Total pharmacy and hardware sales 5,196 2,391 7,587 Service sales: Software integration — 3,168 3,168 Software — 25 25 Maintenance and support — 40 40 Installation — 28 28 Professional services and other — 20 20 Total service sales — 3,281 3,281 Total sales 5,196 5,672 10,868 Cost of sales 5,059 400 5,459 Gross profit $ 137 $ 5,272 $ 5,409 (1) Includes $1.5 million of hardware sales and $3.2 million of software integration sales associated with a non-recurring commercial agreement.
Schedule of Assets and Liabilities by Segment	The following table presents assets and liabilities by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Corporate Total September 30, 2021 Assets $ 11,867 $ 4,740 $ 35,490 $ 52,097 Liabilities $ 5,976 $ 4,108 $ 10,795 $ 20,879 December 31, 2020 Assets $ 6,012 $ 5,547 $ 57,772 $ 69,331 Liabilities $ 2,203 $ 3,422 $ 2,639 $ 8,264 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets, in thousands: September 30, December 31, 2021 2020 Long-lived assets: United States $ 7,108 $ 4,533 Canada 426 501 Total long-lived assets $ 7,534 $ 5,034

NATURE OF OPERATIONS (Details)

NATURE OF OPERATIONS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (11,273)	$ (2,488)	$ (31,189)	$ (14,714)
Operating cash flows			(28,174)	$ (15,327)
Accumulated deficit	$ (179,464)		$ (179,464)		$ (148,275)

EARNINGS (LOSS) PER SHARE - War

EARNINGS (LOSS) PER SHARE - Warrants Included in Earnings per Share (Details)	9 Months Ended
	Sep. 30, 2021shares
Warrants Issued May 9, 2018
Common
Warrants (in shares)	118,228
Warrants Issued February 11, 2020
Common
Warrants (in shares)	309,698
Warrants Issued June 29, 2020
Common
Warrants (in shares)	84,911
Warrants Issued November 18, 2020
Common
Warrants (in shares)	58,518

EARNINGS (LOSS) PER SHARE - Nar

EARNINGS (LOSS) PER SHARE - Narrative (Details) shares in Millions	Nov. 17, 2020	Sep. 30, 2021shares	Sep. 30, 2020shares
Earnings Per Share [Abstract]
Stock split, conversion ratio	1.26
Potentially dilutive option awards excluded from earnings per share calculation (in shares)		2.9	2.2

EARNINGS (LOSS) PER SHARE - Cal

EARNINGS (LOSS) PER SHARE - Calculation of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net loss - basic and diluted	$ (11,273)	$ (2,488)	$ (31,189)	$ (14,714)
Weighted average shares outstanding - basic (in shares)	32,750,831	2,045,686	32,580,199	1,936,015
Weighted average shares outstanding - diluted (in shares)	32,750,831	2,045,686	32,580,199	1,936,015
Net loss per share - basic (in USD per share)	$ (0.34)	$ (1.22)	$ (0.96)	$ (7.60)
Net loss per share - diluted (in USD per share)	$ (0.34)	$ (1.22)	$ (0.96)	$ (7.60)

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 35,875	$ 57,936
Restricted cash	400	60
Total assets	36,275	57,996
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	35,875	57,936
Restricted cash	400	60
Total assets	36,275	57,996
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	$ 0	$ 0

BALANCE SHEET AND OTHER INFOR_3

BALANCE SHEET AND OTHER INFORMATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Inventory [Line Items]
Restricted cash	$ 400		$ 400		$ 60
Depreciation of property, plant, and equipment	300	$ 300	928	$ 721
Depreciation included in cost of sales	40	50	130	150
Amortization of intangible assets	90	10	190	70
Operating lease, expense	300	200	700	500
Pharmacy
Inventory [Line Items]
Inventory recognized as cost of sales	5,000	1,900	12,200	4,800
MedCenter
Inventory [Line Items]
Inventory recognized as cost of sales	130	$ 40	480	$ 140
Guarantee for Purchasing Cards
Inventory [Line Items]
Cash released from restriction	60
Letter of Credit Security
Inventory [Line Items]
Restricted cash	$ 400		$ 400

BALANCE SHEET AND OTHER INFOR_4

BALANCE SHEET AND OTHER INFORMATION - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
MedCenter hardware	$ 1,739	$ 1,655
Pharmacy	1,985	837
Spare parts	529	325
Total inventories	$ 4,253	$ 2,817

BALANCE SHEET AND OTHER INFOR_5

BALANCE SHEET AND OTHER INFORMATION - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Historical cost	$ 9,927	$ 8,246
Accumulated depreciation	(5,295)	(4,451)
Total property, plant and equipment, net	$ 4,632	3,795
MedCenter equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
Historical cost	$ 5,268	4,622
IT equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 2,269	1,999
IT equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	1 year
IT equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	3 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Historical cost	$ 866	799
General plant and equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 567	353
General plant and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
General plant and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	8 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 369	329
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	8 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
Historical cost	$ 54	54
Construction-in-process
Property, Plant and Equipment [Line Items]
Historical cost	$ 534	$ 90

BALANCE SHEET AND OTHER INFOR_6

BALANCE SHEET AND OTHER INFORMATION - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	$ 8,171	$ 6,255
Accumulated amortization	(6,221)	(6,028)
Total intangible assets, net	1,950	227
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	3,857	3,857
Accumulated amortization	(3,857)	(3,857)
Software
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	3,731	1,815
Accumulated amortization	(1,781)	(1,588)
Website and mobile application
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	583	583
Accumulated amortization	$ (583)	$ (583)

BALANCE SHEET AND OTHER INFOR_7

BALANCE SHEET AND OTHER INFORMATION - Leases, Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]
Assets
Operating	$ 2,720	$ 1,108
Finance	182	131
Total assets	2,902	1,239
Operating:
Current	661	612
Long-term	2,178	572
Finance:
Current	81	53
Long-term	101	79
Total liabilities	$ 3,021	$ 1,316

BALANCE SHEET AND OTHER INFOR_8

BALANCE SHEET AND OTHER INFORMATION - Additional Lease Information (Details)	Sep. 30, 2021	Dec. 31, 2020
Finance leases:
Weighted-average remaining lease term (years)	1 year 9 months 18 days	2 years 4 months 24 days
Weighted-average discount rate	8.70%	6.00%
Operating leases:
Weighted-average remaining lease term (years)	4 years 1 month 6 days	2 years 6 months
Weighted-average discount rate	6.80%	6.00%

BALANCE SHEET AND OTHER INFOR_9

BALANCE SHEET AND OTHER INFORMATION - Leases, Operating Lease Liability Maturity (Details) $ in Thousands	Sep. 30, 2021USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2021	$ 176
2022	884
2023	773
2024	562
2025	478
2026	410
Thereafter	26
Total lease payments	3,309
Less: present value discount	(470)
Total leases	$ 2,839

BALANCE SHEET AND OTHER INFO_10

BALANCE SHEET AND OTHER INFORMATION - Leases, Finance Lease Liability Maturity (Details) $ in Thousands	Sep. 30, 2021USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2021	$ 24
2022	95
2023	65
2024	19
2025	0
2026	0
Thereafter	0
Total finance lease payments	203
Less: imputed interest	(21)
Total leases	$ 182

DEBT - Schedule of Debt (Detail

DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total debt, net	$ 10,466	$ 2,161
Less short term debt	(1,000)	(2,161)
Long-term debt, net	9,466	0
Short-term note due May 2021 | Other Payables
Debt Instrument [Line Items]
Short-term notes	0	1,000
Short-term note due November 2021 | Other Payables
Debt Instrument [Line Items]
Short-term notes	1,000	1,000
PPP loan | Notes Payable to Banks
Debt Instrument [Line Items]
Long-term loans	0	161
Term loan | Secured Debt
Debt Instrument [Line Items]
Long-term loans	10,039	0
Term loan issuance costs, net	$ (573)	$ 0

DEBT - Narrative (Details)

DEBT - Narrative (Details) - USD ($)	Jun. 07, 2021	May 14, 2021	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument [Line Items]
Repayment of debt			$ 1,000,000	$ 0
Short-term note due May 2021 | Other Payables
Debt Instrument [Line Items]
Repayment of debt		$ 1,000,000
Term loan | Secured Debt
Debt Instrument [Line Items]
Principal amount	$ 10,000,000
Additional borrowing capacity available	$ 20,000,000
Debt instrument, interest rate floor	7.25%
Interest rate at end of period			7.25%
Debt final payment fee, percentage	4.75%
Debt issuance costs, gross	$ 600,000
Term loan | Secured Debt | Prepayment before June 7, 2022
Debt Instrument [Line Items]
Debt prepayment fee, percentage	3.00%
Term loan | Secured Debt | Prepayment before June 7, 2023
Debt Instrument [Line Items]
Debt prepayment fee, percentage	2.00%
Term loan | Secured Debt | Prepayment after June 7, 2023
Debt Instrument [Line Items]
Debt prepayment fee, percentage	1.00%
Term loan | Secured Debt | Prime Rate
Debt Instrument [Line Items]
Variable interest rate spread	4.00%

SHARE-BASED COMPENSATION EXPE_3

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS - Share Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Equity [Abstract]
Share-based compensation	$ 365	$ 65	$ 948	$ 235

SHARE-BASED COMPENSATION EXPE_4

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 365	$ 65	$ 948	$ 235
Expense remaining to be recognized	$ 3,800		$ 3,800
Weighted average recognition period (in years)			3 years
Aggregate shares on common stock available for grant (in shares)	4,200,000		4,200,000		5,000,000
Warrants issued during the period (in shares)			0
Proceeds from warrant exercises			$ 151
Common Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of warrants (in shares)	171,191		794,804
Investors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants (in shares)	626,339		626,339
Investors | Common Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of warrants (in shares)			565,496
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 30		$ 30
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense remaining to be recognized	$ 1,400		$ 1,400
Weighted average recognition period (in years)			2 years 8 months 12 days
Granted (in shares)			285,899
Grant date fair value of awards granted (in USD per share)			$ 6.50
Aggregate intrinsic value of awards granted			$ 1,900
Number of vested awards (in shares)	0		0

SHARE-BASED COMPENSATION EXPE_5

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2021
Number of Awards
Outstanding awards at beginning of period (in shares)	2,439,020
Granted (in shares)	670,850
Shares issued for options exercisesd/released (in shares)	(144,101)
Awards cancelled/forfeited (in shares)	(1,909)
Outstanding awards at end of period (in shares)	2,963,860
Awards vested and exercisable (in shares)	1,854,062
Awards vested and unvested exercisable (in shares)	1,854,062
Awards vested and expected to vest (in shares)	2,865,212
Weighted Average Exercise Price
Weighted average exercise price of awards outstanding at beginning of period (in USD per share)	$ 1.59
Weighted average exercise price of awards granted (in USD per share)	8.14
Weighted average exercise price of awards exercised/released (in USD per share)	1.67
Weighted average exercise price of awards cancelled/forfeited (in USD per share)	1.65
Weighted average exercise price of awards outstanding at end of period (in USD per share)	3.05
Weighted average exercise price of awards vested and exercisable (in USD per share)	1.88
Weighted average exercise price of awards vested and unvested exercisable (in USD per share)	1.88
Weighted average exercise price of awards vested and expected to vest (in USD per share)	2.98
Weighted average share price on date of exercise (in USD per share)	14.66
Weighted Average Fair Value
Weighted average fair value of awards outstanding at beginning of period (in USD per share)	0.77
Grant date fair value of options granted (in USD per share)	4.44
Weighted average fair value of awards exercised/released (in USD per share)	0.83
Weighted average fair value of awards cancelled/forfeited (in USD per share)	0.83
Weighted average fair value of awards outstanding at end of period (in USD per share)	1.59
Weighted average fair value of awards vested and exercisable (in USD per share)	0.91
Weighted average fair value of awards vested and unvested exercisable (in USD per share)	0.91
Weighted average fair value of awards vested and expected to vest (in USD per share)	$ 1.55
Weighted Average Remaining Contractual Life (Years)
Outstanding, end of period	7 years 11 months 26 days
Vested and exercisable, end of the period	7 years 4 months 2 days
Vested and unvested exercisable, end of the period	7 years 4 months 2 days
Vested and expected to vest, end of the period	7 years 11 months 12 days
Aggregate Intrinsic Value
Aggregate intrinsic value of awards outstanding at beginning of period	$ 32,791
Aggregate intrinsic value of awards granted	0
Aggregate intrinsic value of awards exercised/released	1,872
Aggregate intrinsic value of awards cancelled/forfeited	24
Aggregate intrinsic value of awards outstanding at end of period	3,173
Aggregate intrinsic value of awards vested and exercisable	2,438
Aggregate intrinsic value of awards vested and unvested exercisable	2,348
Aggregate intrinsic value of awards vested and expected to vest	$ 3,122

REVENUE AND SEGMENT REPORTING -

REVENUE AND SEGMENT REPORTING - Narrative (Details) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2021segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Segment Reporting, Revenue Reconciling Item [Line Items]
Number of reportable segments | segment	2
Contract liability			$ 4.7
Contract revenue recognized		$ 4.7
Hardware
Segment Reporting, Revenue Reconciling Item [Line Items]
Contract revenue recognized		1.5
Other Revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Contract revenue recognized		$ 3.2

REVENUE AND SEGMENT REPORTING_2

REVENUE AND SEGMENT REPORTING - Schedule of Revenue and Cost of Sales (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	$ 5,792	$ 7,145	$ 14,849	$ 10,868
Total cost of sales	5,606	2,162	14,170	5,459
Gross profit	186	4,983	679	5,409
Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	5,445	2,186	13,357	5,196
Total cost of sales	5,366	2,042	13,130	5,059
Gross profit	79	144	227	137
Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	347	4,959	1,492	5,672
Total cost of sales	240	120	1,040	400
Gross profit	107	4,839	452	5,272
Retail pharmacy sales
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	5,445	2,186	13,357	5,196
Retail pharmacy sales | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	5,445	2,186	13,357	5,196
Retail pharmacy sales | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Hardware
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	106	1,625	470	2,048
Hardware | Fair Value, Nonrecurring
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales		1,500
Hardware | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Hardware | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	106	1,625	470	2,048
Subscription sales
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	108	115	338	343
Subscription sales | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Subscription sales | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	108	115	338	343
Total pharmacy and hardware sales
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	5,659	3,926	14,165	7,587
Total cost of sales	5,539	2,132	13,744	5,343
Total pharmacy and hardware sales | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	5,445	2,186	13,357	5,196
Total pharmacy and hardware sales | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	214	1,740	808	2,391
Software integration
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	3,168	0	3,168
Software integration | Fair Value, Nonrecurring
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales		3,200
Software integration | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Software integration | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales		3,168	0	3,168
Software
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	51	15	125	25
Software | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Software | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	51	15	125	25
Maintenance and support
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	44	17	115	40
Maintenance and support | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Maintenance and support | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	44	17	115	40
Installation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	11	0	39	28
Installation | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Installation | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	11	0	39	28
Professional services and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	27	19	405	20
Professional services and other | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Professional services and other | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	27	19	405	20
Total service sales
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	133	3,219	684	3,281
Total cost of sales	67	30	426	116
Total service sales | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Total service sales | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	$ 133	$ 3,219	$ 684	$ 3,281

REVENUE AND SEGMENT REPORTING_3

REVENUE AND SEGMENT REPORTING - Schedule of Assets and Liabilities by Segment (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 52,097	$ 69,331
Liabilities	20,879	8,264
Operating Segments | Retail Pharmacy Services
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	11,867	6,012
Liabilities	5,976	2,203
Operating Segments | Pharmacy Technology
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	4,740	5,547
Liabilities	4,108	3,422
Corporate
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	35,490	57,772
Liabilities	$ 10,795	$ 2,639

REVENUE AND SEGMENT REPORTING_4

REVENUE AND SEGMENT REPORTING - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	$ 7,534	$ 5,034
United States
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	7,108	4,533
Canada
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	$ 426	$ 501